Publications by authors named "H Lapeere"

Claim this Profile
E
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.
Matthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, Marjolein S de Bruin-Weller, Khaled Ezzedine, Hilde Lapeere

BMJ Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
Piergiacomo Calzavara-Pinton, Chia-Yu Chu, Hilde Lapeere, Mariateresa Rossi, Silvia M Ferrucci

Adv Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).
Jeroen Geldof, Marie Truyens, João Sabino, Marc Ferrante, Jo Lambert, Hilde Lapeere

Vaccines (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
A H Musters, F L van Lookeren, L F van der Gang, M A Middelkamp-Hup, A L Bosma, H Lapeere

J Eur Acad Dermatol Venereol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belgian atopic dermatitis guidelines.
Hilde Lapeere, Reinhart Speeckaert, Marie Baeck, Bita Dezfoulian, Julien Lambert

Acta Clin Belg· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis